logo

menu closed
top

COMPANY PIPELINE

pipeline

FIRST-IN-CLASS ANTI-CANCER DRUG : SMALL MOLECULE WITH NOVEL DUAL ACTION MECHANISM

program pipeline indication
Development Stage
drug
development
lead
optimization
Pre-clinical Toxicity Clinical
SMALL
MOLECULE
OZ-001 NSCLC Toxicity
Pancreatic cancer Toxicity
TNBC Toxicity
· SECURE PATENT OF OZ-001

FIRST-IN-CLASS DRUG : NOVEL CMPD DEGRADER (Chaperone-Medicated Protein Degradation)

program pipeline indication
Development Stage
DRUG
DEVELOPMENT
LEAD
OPTIMIZATION
Pre-clinical Toxicity Clinical
CMPD
OZ-003 Resistant NSCLC Pre-clinical
OZ-004 Mutation GIST LEAD OPTIMIZATION
OZ-005 Biliary tract Cancer LEAD OPTIMIZATION
OZ-006 Undisclosed (Tentative target : Tau) DRUG DEVELOPMENT
OZ - 001 OZ - 002 OZ - 003 0Z - 004 OZ - 005 0Z - 006

OZ-001 MODE OF ACTION: A Novel Dual-Targeting Anti-Cancer Small Molecule

OZ-001 is an innovative anti-cancer small molecule designed with a dual-targeting mechanism, uniquely inhibiting both T-type calcium channels and STAT3 signaling. This dual approach positions OZ-001 as a highly promising single-agent therapy for cancer by:

➀ Inhibiting T-type calcium channels: Reduces intracellular calcium levels, suppresses CaMK2 phosphorylation, induces cell cycle arrest,and effectively inhibits tumor growth.
➁ Targeting the STAT3 pathway: Blocks the STAT3 signaling pathway, driving cancer cell apoptosis and enhancing anti-tumor effects.

Together, these complementary mechanisms position OZ-001 as a groundbreaking therapeutic agent with the potential to significantly slow cancer progression and induce cancer cell death.



Development Status
OZ-001 has undergone comprehensive in-vitro and in-vivo studies, including efficacy evaluations, mechanism research, and toxicity studies, across three target indications:
triple-negative breast cancer (TNBC), pancreatic cancer, and non-small cell lung cancer (NSCLC).
The IND filing for OZ-001 was successfully completed in Australia, and we are preparing to initiate clinical trials in 2025.

New Target for Cancer Therapy : Calponin 3 Protein

The Calponin Family of actin-binding proteins consists of three isoforms:
① Calponin- 1 (CNN1; h1 or basic CNN); ②CNN2 (h2 or neutral CNN); and ③CNN3 (h3 or acidic CNN).
All of them are generally involved in various forms of cell motility.

- Calponin 3 (CNN3)

  • Actin-binding Protein
  • Expressed in Smooth muscle and Non-smooth muscle cells
  • High level expression in Smooth muscle, Placental Trophoblast, Myoblast
  • Required for Cytoskeletal Rearrangement & Wound Healing
  • Paly a role in Cell Differentiation, Proliferation and Migration via stress fibre formation or cytoskeletal remodeling
  • In recent studies of CNN3 for Caner
    Differentially Expressed in Colorectal, Breast, Cervical, Gastric, Ovarian cancer, MALT lymphoma and etc.
    Showed association with EMT Features, increased Cancer cell Invasion and Resistance to chemotherapeutic agents
    High expression is associated with Tumor Size, Tumor Stage and Lymph node and Distant metastases.

IN PROGRESS

  • We confirmed based on our own study that CNN3 is expressed in various cancer cell line and it is overexpressed especially in rhabdomyosarcoma.
  • We confirmed anti-cancer drug effect of OZ-002 in orphan cancer cell line related myosarcoma.
  • Ongoing, rapidly we are identifying correlation with overexpression of CNN3 in various cell line related myosarcoma to develop first-in-class drug targeting CNN3 as biomarker.
  • Ongoing, we are under studying for other various cancer which has differentially expression of CNN3.

REFERENCE

  • World J Gastrointest Oncol 2019 November 15; 11(11): 971-982
  • AGING 2020, Vol. 12, No. 14
  • Hindawi Gastroenterology Research and Practice Volume 2019, Article ID 3024970, 7 pages
  • Scientific RepoRtS 2020, 10:2427

OZ-003: Targeting c-MET in NSCLC

OZ-003 is designed to target c-MET, a critical driver of drug resistance in existing EGFR inhibitors for the treatment of non-small cell lung cancer (NSCLC).
As the most advanced program within the CMPD portfolio, OZ-003 has demonstrated efficacy in preclinical animal studies, establishing its potential as a transformative therapy for NSCLC.

OZ-004: Targeting c-KIT for GIST

OZ-004 focuses on c-KIT, a key therapeutic target for the treatment of gastrointestinal stromal tumors (GIST).
Currently in the lead optimization stage, this program is actively evaluating efficacy through xenograft animal models to refine its therapeutic profile.

OZ-005: Targeting HER for Biliary Tract Cancer

OZ-005 is centered on HER (Human Epidermal Growth Factor Receptor) as a novel approach to treat biliary tract cancer.
This program is also in the lead optimization stage, with ongoing studies to validate its efficacy and therapeutic potential.

OZ-006: Targeting Tau for Neurodegenerative Diseases

OZ-006 is aimed at targeting Tau, a key protein implicated in the progression of neurodegenerative diseases such as Alzheimer’s disease.
This program is currently in the drug development stage, focusing on the design and synthesis of novel OZ Degraders.